Specifically, prostate cancer patients with low CD8 +/strong PRSS2 expression or high FoxP3 +/strong PRSS2 expression had significantly poorer outcome (Fig. 7G, H and Supplementary Fig. S11). This evidence concerns the gene CD8A and prostate carcinoma.